April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
The U.S. FDA approval of Odefsey "is a nice advance, especially for those patients at risk for renal and/or bone disease," writes Paul Sax, M.D.
On March 1, 2016, a new single tablet regimen (STR) was approved by the U.S. FDA for treating HIV infection. Called Odefsey, the new once-a-day pill is comprised of three HIV drugs: emtricitabine, rilpivirine and tenofovir alafenamide (TAF).
The FDA has approved a new once-daily drug regimen for the treatment of HIV. Odefsey, by Gilead Sciences, is composed of emtricitabine, rilpivirine and tenofovir alafenamide.
Switching to Emtricitabine/Tenofovir Alafenamide (F/TAF) Maintains Viral Suppression With Better Bone and Kidney Safety
Switching from treatment regimens containing tenofovir/emtricitabine (Truvada, F/TDF) to regimens containing emtricitabine/tenofovir alafenamide (F/TAF) maintains undetectable viral loads and improves renal and bone safety, according to a CROI 2016 s...